

Be a part of the future in diabetes research

If you are an adult with type 2 diabetes mellitus, you may be eligible to take part in a clinical research study called CARMELINA.

The purpose of the CARMELINA Study is to look at the impact of an investigational drug called linagliptin on the long-term occurrence of selected complications of cardiovascular disease (e.g. stroke or heart attack) in people with type 2 diabetes mellitus receiving standard of care.

You may be eligible to take part in the CARMELINA Study if:

- ✓ you are 18 years of age or older
- ✓ you have been diagnosed with type 2 diabetes mellitus
- ✓ you have been receiving a stable dose of antidiabetic medication for at least 8 weeks **or** you have not previously received antidiabetic treatment
- ✓ you have previously had problems with your heart (cardiovascular disease) and/or kidneys (renal disease).

If you participate in the study, you will take the study drug (linagliptin or placebo) once every day. You will be provided with an electronic device called a glucometer to measure your blood sugar levels once every week (or as agreed with your study doctor), or whenever you feel symptoms of your diabetes.

Depending on when you join the study, your participation could last for a period of up to approximately 4.5 years. You will need to visit the study center a number of times so the study doctor can assess your diabetes and overall health. Most study visits will take place every 24 weeks (6 months). The study doctor will tell you when the study will be ending.

For more information about the CARMELINA Study, please contact: